A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of Rimonabant 20 mg Daily for the Treatment of Type 2 Diabetic Patients With Nonalcoholic Steatohepatitis (NASH).

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of Rimonabant 20 mg Daily for the Treatment of Type 2 Diabetic Patients With Nonalcoholic Steatohepatitis (NASH).

Discontinued
Phase of Trial: Phase III

Latest Information Update: 30 May 2016

At a glance

  • Drugs Rimonabant (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Acronyms STRONG2
  • Sponsors Sanofi
  • Most Recent Events

    • 28 Jul 2011 New source identified and integrated (European ClinicalTrials Database).
    • 17 Jun 2009 Actual patient number (89) added as reported by ClinicalTrials.gov.
    • 17 Jun 2009 Actual initiation date changed from 1 Dec 2007 to 1 Feb 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top